ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Phase III Study In Treatment-naive Adults With HIV Evaluates Efficacy And Safety Of Once Daily PREZISTA/RITONOVIR Vs. KALETRA
Results from an ongoing Phase III ARTEMIS study that examines an investigational 800mg* once daily dose of PREZISTA® (darunavir/ritonavir) versus KALETRA®1 (lopinavir/ritonavir) 400 mg/100 mg twice daily (or 800 mg/200 mg once daily depending on the local licence) in treatment-naïve adults** with HIV-1, successfully met the primary end point of non-inferiority (95% confidence internal with the lower limit for the difference in treatment response -12% or greater for HIV RNA of less than 50 copies per mL in plasma at week 48). Of the patients taking darunavir/r, 84% reached an undetectable viral load (
În studiul de fazã III Tratamentul-naiv adulþii cu HIV evalueazã eficacitatea ºi siguranþa, o datã pe zi PREZISTA / RITONOVIR Vs. KALETRA - Phase III Study In Treatment-naive Adults With HIV Evaluates Efficacy And Safety Of Once Daily PREZISTA/RITONOVIR Vs. KALETRA - articole medicale engleza - startsanatate
